Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Trends in Patient Outcome Over the Past Two Decades Following Allogeneic Stem Cell Transplantation for Acute Myeloid Leukaemia: An Alwp/Ebmt Analysis Publisher Pubmed



Canaani J1 ; Beohou E2 ; Labopin M2 ; Ghavamzadeh A3 ; Beelen D4 ; Hamladji RM5 ; Niederwieser D6 ; Volin L7 ; Markiewicz M8 ; Arnold R9 ; Mufti G10 ; Ehninger G11 ; Socie G12 ; Kroger N13 Show All Authors
Authors
  1. Canaani J1
  2. Beohou E2
  3. Labopin M2
  4. Ghavamzadeh A3
  5. Beelen D4
  6. Hamladji RM5
  7. Niederwieser D6
  8. Volin L7
  9. Markiewicz M8
  10. Arnold R9
  11. Mufti G10
  12. Ehninger G11
  13. Socie G12
  14. Kroger N13
  15. Mohty M2
  16. Nagler A1, 2
Show Affiliations
Authors Affiliations
  1. 1. Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel
  2. 2. Acute Leukemia Working Party –EBMT and Department of Hematology and Cell Therapy, Hopital Saint-Antoine, Paris, France
  3. 3. Hematology-Oncology and BMT Research, Shariati Hospital, Teheran, Iran
  4. 4. Department of Bone Marrow Transplantation, University Hospital, Essen, Germany
  5. 5. Service Hematologie Greffe de Moelle, Centre Pierre et Marie Curie, Alger, Algeria
  6. 6. Division of Haematology & Oncology, University Hospital Leipzig, Leipzig, Germany
  7. 7. Stem Cell Transplantation Unit, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
  8. 8. Department of Haematology and BMT, Medical University of Silesia, Katowice, Poland
  9. 9. Medizinische Klinik m. S. Hamatologie/Onkologie, Charite Universitaetsmedizin Berlin, Berlin, Germany
  10. 10. Department of Haematological Medicine, GKT School of Medicine, London, United Kingdom
  11. 11. Universitaetsklinikum Dresden Medizinische Klinik und Poliklinik I, Dresden, Germany
  12. 12. Department of Hematology – BMT, Hopital St. Louis, Paris, France
  13. 13. Bone Marrow Transplantation Centre, University Hospital Eppendorf, Hamburg, Germany

Source: Journal of Internal Medicine Published:2019


Abstract

Background: Outcomes for patients with acute myeloid leukaemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) have significantly improved in recent years. Objectives: To assess the incremental improvement of transplanted AML patients in the last two decades. Methods: Patients included in this analysis were adult AML patients who underwent allo-SCT from an HLA-matched sibling donor (MSD) or HLA-matched unrelated donor (MUD) in first remission. Patient outcomes were assessed between three cohorts according to the year of transplant (1993–2002, 2003–2007 and 2008–2012). Results: The analysis comprised a total of 20 187 patients of whom 4763 were transplanted between 1993 and 2002, 5835 in 2003 and 2007, and 9589 in 2008 and 2012. In multivariate analysis, leukaemia-free survival (LFS) rates were significantly improved in more recently transplanted patients compared to patients transplanted in 1993–2002 [Hazard ratio (HR) = 0.84, confidence interval (CI) 95%, 0.77–0.92; P = 0.003], a benefit which also extended to improved overall survival (OS; HR = 0.8, CI 95%, 0.73–0.89; P < 0.0001), and decreased nonrelapse mortality (NRM) rates (HR = 0.65, CI 95%, 0.56–0.75; P < 0.0001). Subset analysis revealed that in MSD, the rates of LFS, NRM and OS significantly improved in patients in the more recent cohort with similar results also seen in MUD. Finally, the incidence of acute graft-versus-host disease (GVHD) was significantly reduced leading to improved GVHD-free/relapse-free survival (GRFS) rates in more recently transplanted patients. Conclusion: Outcome of allo-SCT for AML patients has markedly improved in the last two decades owing to decreased nonrelapse mortality and improved rates of leukaemia-free survival resulting in significantly longer survival. © 2018 The Association for the Publication of the Journal of Internal Medicine
Related Docs
View other Related Docs
1. What Is the Outcome in Patients With Acute Leukaemia Who Survive Severe Acute Graft-Versus-Host Disease?, Journal of Internal Medicine (2018)
2. Refined Graft-Versus-Host Disease/Relapse-Free Survival in Transplant From Hla-Identical Related or Unrelated Donors in Acute Myeloid Leukemia, Bone Marrow Transplantation (2018)
3. Comparable Outcomes of Allogeneic Peripheral Blood Versus Bone Marrow Hematopoietic Stem Cell Transplantation in Major Thalassemia: A Multivariate Long-Term Cohort Analysis, Biology of Blood and Marrow Transplantation (2019)
4. A Single-Center Experience With Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia: A Modest Pitch for Non-Total Body Irradiation Conditioning Regimens, Experimental and Clinical Transplantation (2019)
5. Survival of Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation: An Experience in Developing Country, International Journal of Hematology-Oncology and Stem Cell Research (2022)
6. Dendritic Cell Vaccination Strategy for the Treatment of Acute Myeloid Leukemia: A Systematic Review, Cytotherapy (2024)
7. Ultrasensitive Quantitation of Flt3-Itd Mutation in Patients With Acute Myeloid Leukemia Using Ddpcr, Molecular Biology Reports (2023)
8. Impact of Anti-Thymocyte Globulin on Results of Allogeneic Peripheral Blood Stem Cell Transplantation for Patients With Philadelphia-Positive Acute Lymphoblastic Leukaemia: An Analysis by the Acute Leukemia Working Party of the Ebmt, European Journal of Cancer (2019)
Experts (# of related papers)
View all Related Experts
Amir Kasaeian (2)
Mohammad Vaezi (1)
Other Related Docs
9. Transplantation, Clinical Immunology (2022)
10. Prognostic Value of Runx1 Mutations in Aml: A Meta-Analysis, Asian Pacific Journal of Cancer Prevention (2018)
11. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older: A Systematic Review and Meta-Analysis, Transplantation and Cellular Therapy (2025)
12. Conditioning Intensity in Middle-Aged Patients With Aml in First Cr: No Advantage for Myeloablative Regimens Irrespective of the Risk Group-An Observational Analysis by the Acute Leukemia Working Party of the Ebmt, Bone Marrow Transplantation (2015)